Does Anthem (Elevance Health) Cover Trazodone?

Anthem's Formulary Placement for Trazodone

Generic trazodone hydrochloride sits on the preferred generic tier across most Anthem (Elevance Health) commercial formularies. This means the lowest copay bracket applies, often $0 to $10 for a 30-day supply at a network pharmacy.

Anthem operates multiple formulary lists depending on the plan type (PPO, HMO, EPO) and the employer group's selected benefit design. The specific tier can shift between Tier 1 and Tier 2. Checking your plan's formulary drug list on the Anthem member portal or calling the number on the back of your insurance card confirms exact placement. Trazodone has been available as a generic since 1981, and its low acquisition cost keeps it on preferred tiers across nearly all commercial insurers [1]. The FDA first approved trazodone for major depressive disorder in 1981 under the brand name Desyrel, and its prescribing information details the approved dosing range of 150 to 400 mg/day for depression.

Brand-name extended-release trazodone (Oleptro) carried a higher tier and sometimes required prior authorization. Oleptro was discontinued in 2016, so the generic immediate-release formulation is the version most prescribers and pharmacies dispense today.

Prior Authorization Requirements on Anthem Plans

Anthem flags trazodone for prior authorization primarily when the prescribed dose exceeds standard ranges or when the diagnosis falls outside the FDA-approved indication. Moderate difficulty describes the PA process for this drug, meaning most requests are approved within 48 to 72 hours when documentation is complete.

PA triggers on Anthem plans typically include doses above 400 mg/day, use in pediatric populations under 18, or concurrent prescriptions of multiple sedating medications. For the depression indication at standard doses (150 to 300 mg/day in divided doses), many Anthem plans dispense trazodone without any PA at all. The requirement varies by employer group and state.

When PA is required, the prescribing clinician submits clinical documentation including the diagnosis (ICD-10 code), prior medication trials, dosing rationale, and relevant lab work. Anthem's pharmacy benefit manager reviews the request against clinical criteria adapted from sources like the American Psychiatric Association practice guidelines for depressive disorders [2]. A 2022 APA guideline update recommends trazodone as a second-line option for MDD, particularly when insomnia is a prominent symptom.

The prescriber's office can expedite an urgent PA by calling Anthem's pharmacy prior authorization line and requesting a 24-hour review. Standard reviews take up to 72 hours. Denials must include a written explanation and instructions for appeal.

Step Therapy Protocols for Trazodone

Some Anthem plans require step therapy before covering trazodone for depression. The typical step therapy sequence mandates a trial and documented failure (or intolerance) of at least one first-line SSRI (such as sertraline or escitalopram) before trazodone is approved.

This requirement reflects current prescribing guidelines. The APA's 2022 practice guideline positions SSRIs and SNRIs as first-line pharmacotherapy for major depressive disorder, with trazodone recommended when patients cannot tolerate first-line agents or when insomnia complicates the clinical picture [2]. Anthem's step therapy criteria mirror this evidence hierarchy.

Step therapy does not usually apply when trazodone is prescribed at low doses (25 to 100 mg) specifically for insomnia, though this depends on the plan. Off-label insomnia use is widespread: a 2014 analysis found trazodone was the most commonly prescribed medication for insomnia in the United States, with an estimated 5.3 million prescriptions annually for that indication alone [3]. Mendelson's 2005 study in the Journal of Clinical Psychiatry examined trazodone's hypnotic efficacy and found statistically significant improvements in sleep latency and total sleep time at doses of 50 to 100 mg, though the effect diminished after two weeks of continuous use [4].

To bypass step therapy, the prescriber can submit a step therapy exception request documenting clinical reasons why first-line agents are inappropriate. Valid reasons include prior adverse reactions, drug interactions with current medications, or a documented history of SSRI failure within the past 12 months.

Off-Label Insomnia Coverage on Anthem

Anthem does not explicitly exclude off-label insomnia as a covered indication for trazodone, but coverage varies by plan. Many prescribers write trazodone prescriptions with a depression diagnosis code even when the primary clinical target is sleep, since dual benefit is common.

Low-dose trazodone (25 to 100 mg at bedtime) for insomnia represents one of the most common off-label uses in American psychiatry. The American Academy of Sleep Medicine's 2017 clinical practice guideline gave a conditional recommendation against trazodone for chronic insomnia due to limited long-term efficacy data, while acknowledging its widespread real-world use [5]. A meta-analysis published in the Annals of Internal Medicine covering 154 randomized trials of insomnia pharmacotherapy found that trazodone improved subjective sleep quality with a standardized mean difference of 0.34 (95% CI 0.05 to 0.63) compared to placebo [6].

If Anthem denies coverage for trazodone prescribed for insomnia, the prescriber has two options. First, document a comorbid depressive disorder if clinically appropriate. Second, submit a formulary exception request with published evidence supporting off-label use and a letter of medical necessity.

How to Appeal a Denied Trazodone Claim

Anthem provides a two-level internal appeal process followed by an external independent review. Fast action matters. Anthem requires first-level internal appeals within 180 days of the denial notice.

Step 1: First-level internal appeal. Submit a written appeal to the address on the denial letter. Include a letter of medical necessity from the prescriber, relevant clinical records, supporting literature, and the specific denial reference number. Anthem must respond within 30 calendar days for non-urgent pre-service appeals and 60 days for post-service claims.

Step 2: Second-level internal appeal. If the first appeal is denied, file a second-level appeal within 60 days. A different reviewer examines the case. Response timelines match the first level.

Step 3: External review (state IRO). After exhausting internal appeals, members can request an independent review organization evaluation through their state insurance department. The IRO decision is binding on Anthem. Processing typically takes 45 days, or 72 hours for expedited urgent cases.

The Centers for Medicare & Medicaid Services and individual state insurance departments publish appeal rights and timelines that apply to Anthem plans [7]. Keeping copies of every submission, denial letter, and fax confirmation creates a paper trail that strengthens the appeal.

Cost Breakdown: Generic Trazodone With Anthem

Generic trazodone is one of the least expensive psychiatric medications available. The manufacturer list price for brand trazodone sits around $40 per month, but the generic version averages $10 per month at cash-pay prices.

With Anthem insurance, the typical member copay for a Tier 1 generic is $0 to $10 for a 30-day supply. Some high-deductible health plans (HDHPs) require members to pay the full negotiated rate until the deductible is met, which for trazodone usually amounts to $4 to $15.

Patients who face higher-than-expected costs have several options. Pharmacy discount programs through GoodRx, RxSaver, or Amazon Pharmacy often price generic trazodone at $4 to $8 for 30 tablets of the 50 mg strength. These cash prices sometimes beat the insurance copay, especially on HDHP plans before the deductible is satisfied. Using a discount card does not count toward the insurance deductible, so members should calculate which option better serves their annual out-of-pocket strategy.

Mail-order pharmacy benefits through Anthem's preferred mail-order partner (often Express Scripts or CarelonRx) may offer 90-day supplies at a reduced copay, sometimes two copays for a three-month supply. This is worth exploring for patients on stable, long-term trazodone regimens.

Trazodone Dosing and Clinical Context

Understanding approved dosing helps patients anticipate what Anthem is likely to cover without additional review. The FDA-approved dosing range for depression starts at 150 mg/day in divided doses, increasing by 50 mg/day every three to four days to a maximum of 400 mg/day (600 mg/day in hospitalized patients) [1].

For off-label insomnia, most clinicians prescribe 25 to 100 mg taken 30 minutes before bedtime. A 2017 Cochrane review of antidepressants for insomnia found low-quality evidence supporting trazodone's short-term hypnotic effects, noting that most trials lasted only one to two weeks [8]. The Mendelson 2005 trial specifically reported that trazodone 50 mg reduced sleep latency by an average of 10 minutes compared to placebo in the first week, but this difference was no longer statistically significant by week two (P = 0.18) [4].

Common side effects include morning sedation, orthostatic hypotension, dry mouth, and dizziness. Priapism is a rare but serious adverse event occurring in approximately 1 in 6,000 to 8,000 male patients [1]. Patients should report prolonged erections lasting more than four hours to an emergency department immediately.

Trazodone carries a boxed warning for suicidality in children, adolescents, and young adults (ages 18 to 24), consistent with all antidepressants [1]. This warning does not affect Anthem coverage but does influence prescribing patterns in younger populations and may trigger additional PA requirements.

Anthem Marketplace and Medicaid Managed Care Plans

Coverage policies differ between Anthem's commercial plans, ACA Marketplace plans, and Medicaid managed care products. Anthem operates Medicaid managed care plans in multiple states under brands including Amerigroup and CareSource partnerships.

On Marketplace (ACA exchange) plans, trazodone is covered as part of the Essential Health Benefits pharmacy mandate. Every ACA-compliant plan must cover at least one drug in each USP therapeutic category, and trazodone satisfies this requirement within the antidepressant class [7]. Marketplace plan formularies may still apply step therapy or PA, but they cannot exclude the drug category entirely.

Medicaid managed care formularies administered by Amerigroup (an Elevance Health subsidiary) generally place generic trazodone on the preferred drug list with no PA for standard doses. Federal Medicaid rules require coverage of all FDA-approved drugs from manufacturers that participate in the Medicaid Drug Rebate Program, though states can implement preferred drug lists with PA for non-preferred alternatives [9]. Trazodone's generic status and low cost mean it rarely faces Medicaid access barriers.

Comparing Trazodone to Alternatives on Anthem Formularies

Patients denied trazodone or facing step therapy may consider how alternative medications are positioned on Anthem's formulary. SSRIs like sertraline (generic Zoloft) and escitalopram (generic Lexapro) typically sit on the same preferred generic tier as trazodone, with $0 to $10 copays.

For insomnia specifically, Anthem formularies often cover generic zolpidem (Ambien) on a preferred generic tier. Newer branded sleep agents like suvorexant (Belsomra) and lemborexant (Dayvigo) require PA and sit on higher formulary tiers (Tier 3 or specialty), carrying copays of $40 to $75 per month. A 2019 systematic review in the Annals of Internal Medicine compared pharmacotherapies for chronic insomnia and found that orexin receptor antagonists (suvorexant, lemborexant) showed more consistent long-term efficacy data than trazodone, but at substantially higher cost [6].

The Endocrine Society's 2019 clinical practice guideline on testosterone therapy notes that sleep disturbances in hypogonadal men may improve with testosterone replacement, offering another treatment pathway for patients whose insomnia coexists with hormonal deficiency [10].

Generic trazodone's cost advantage is significant. At $4 to $15 per month versus $300 or more for branded sleep medications, trazodone remains a first-choice option for clinicians managing formulary-sensitive patients.